

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Express Mail Label Number EV 590690225 US with sufficient postage, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on

PATENT
Attorney Docket No.: 9632-006-999
Client Reference No.: CD30

December 30, 2005

Date of Deposit


Mark G. Sandbaken, Reg. No. 39,354

Name of Applicant, Assignee or
Registered Representative

Mark G. Sandbaken

December 30, 2005

Date of Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Francisco et al.

Application No.: 09/724,406

Filed: November 28, 2000

For: RECOMBINANT ANTI-CD30
ANTIBODIES AND USES THEREOF

Confirmation No.: 7578

Examiner: Misook Yu

Art Unit: 1642

SIXTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references [excluding cited U.S. Patents, U.S. Patent Application publications, and appropriate IFW-stored, pending U.S. Patent Applications and portions thereof, per 1287 OG 163] are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

The Commissioner is authorized to deduct the fee for this information disclosure statement from Deposit Account No. 502900. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Mark G. Sandbaken, Ph.D.
Reg. No. 39,354

SEATTLE GENETICS, INC.
21823 – 30th Drive SE
Bothell, WA 98021
Tel: 425-527-4138
Fax: 425-527-4001

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/724,406
(use as many sheets as necessary)		Filing Date	11/28/2000
		First Named Inventor	Francisco et al.
		Art Unit	1642
		Examiner Name	Misook Yu
Sheet	1	of	2
		Attorney Docket Number	
		9632-006-999	



U.S. PATENT DOCUMENTS+

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
		WO	97/17374	05-15-1997	Medac Gesellschaft ...	Pages 18-23	<input type="checkbox"/>
		WO	05/001038	A2	Seattle Genetics		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	2	of	2		
				Application Number	10/983,340
				Filing Date	November 5, 2004
				First Named Inventor	Doronina, Svetlana O.
				Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	018891-001020US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Blast 2 Sequences Results (2 pages)	
		BARTLETT et al., "Phase I Study of SGN-30, a Chimeric Monoclonal Antibody (mAb), in Patients with Refractory or Recurrent CD30 + Hematologic Malignancies," <u>BLOOD</u> Vol. 100(11), December, 2002, Abs 1403.	
		Safety, Antitumor Activity and Pharmacokinetics of Six Weekly Doses of SGN-30 (anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies," <u>BLOOD</u> 102(11), 2003, Abs 2390.	
		CERVENY et al., "Hodgkin's disease growth inhibition and sensitization to standard chemotherapeutics by the anti-CD30 monoclonal antibody SGN-30," <u>PROC AM ASSOC CANCER RES</u> vol. 45, March 2004, Abs 2258.	
		CERVENY et al., "Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics," <u>LEUKEMIA</u> 19:1648-1655 (2005).	
		CERVENY et al., "The Anti-CD30 Monoclonal Antibody SGN-30 Inhibits Hodgkins Disease Growth and Sensitizes Cells to Established Chemotherapeutics," <u>BLOOD</u> 104(11), 2004, Abs 2639	
		KABAT et al., <u>Sequences of Proteins of Immunological Interest</u> , 5th Ed., NIH Publication No. 91-3242, pp. xv-xvi.	
		KOON et al., "Anti-CD30 antibody based therapy," <u>CURRENT OPINION IN ONCOLOGY</u> 12:588-593 (2000)	
		LEONARD et al., "Targeting CD30 as Therapy for Hodgkin's Disease. Phase II Results with the Monoclonal Antibody SGN-30," <u>PROC AM SOC CLIN ONCOL</u> April 2005, Abs 2553	
		LEONARD et al., "Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin's Disease," <u>BLOOD</u> 104(11) 2004, Abs 2635.	
		WAHL et al., "The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease," <u>CANCER RES.</u> 62:3736-3742 (2002).	

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.